Clinical Trials

Inclusion Criteria

• Listed patients who are negative for HCV RNA
• Ages 40-65
• MELD score 15-34
• No contra-indications to direct acting antiviral therapy rather than Velpatasvir and Sofosbuvir as there are now two new combinations we can use besides Velpatasvir and Sofosbuvir since the protocol was written
• Not a candidate for a living donor allograft
• Deemed by transplant team to have complication of liver disease refractory to medical therapy or high risk of death and unlikely to receive a liver transplant in the next 24 to 48 weeks
• There are no HCV positive recipients who could accept the donor liver

Exclusion Criteria

• Previous HCV treatment
• HIV or Chronic Hepatitis B.
• DCD or ABO incompatible Donor
• Donor on HCV or with history treatment
• Biopsy of donor liver demonstrating > stage 2 fibrosis.
• Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection
• Hepatocellular carcinoma outside of accepted institutional criteria